Thursday, April 19, 2012

Theralase Reports Expanded Cancer Drug Technology

Toronto, Ontario -- April 19, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that it has been issued a new U.S. Patent that expands the scope and capabilities of its cancer-fighting proprietary Photo Dynamic Compound (PDC) technology. The patent provides Theralase with exclusive rights to a new and advanced class of anti-cancer and anti-bacterial compounds until 2031.
Theralase continues to expand its intellectual property holdings of cancer-fighting drug compounds employed in conjunction with its proprietary therapeutic laser device capabilities. The newly issued U.S. Patent expands the Company’s capability to jointly employ its proprietary PDC and laser technologies in the destruction of a diverse variety of common cancers, bacteria and viruses. The new PDC patent identifies a special class of proprietary Photo Dynamic Compounds that can be employed in the destruction of bulk tumours.
Theralase recently reported that the growth of subcutaneous (under the skin) colon cancer tumours in mouse subjects, which were simultaneously treated with the Theralase anti-cancer PDC technologies have continued to thrive cancer-free for more than 55 days post-treatment and without any side effects.
Based on the Company’s recent successes in the research and development of its portfolio of patented PDCs, there is increased confidence that applications can be made to the regulatory bodies for human trials in the relatively near future.  
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
For further information please visit, regulatory filings may be viewed by visiting  
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:

Roger Dumoulin-White
President & Chief Executive Officer
416-447-8455 ext. 225

Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224

Arkady Mandel
Chief Scientific Officer
416-447-8455 ext. 242

Greg Bewsh
Director of Investor Relations
416-447-8455 ext. 262 

No comments:

Post a Comment